Search		GO	Type Size:				Print This Page
Important Safety Information Full Prescribing Information

This information is intended for US healthcare professionals

Understanding Hyponatremia

Management of Dilutional Hyponatremia

Management of hyponatremia is complicated by the wide range of associated conditions, variable presentation, and the serious and potentially fatal outcomes that may result from improper treatment.¹

Traditional therapies

Traditional treatment options for dilutional hyponatremia, which have been available for quite some time, include²:

Fluid restriction
Hypertonic saline 3% infusion
Diuretics
Demeclocycline
Lithium
Urea

Arginine vasopressin (AVP) antagonists—a new direction in hyponatremia management

Vaprisol is the first in a newer class of agents—AVP receptor antagonists. Vaprisol works through direct antagonism of AVP receptors, resulting in aquaresis—the electrolyte-sparing excretion of free water.³

Rate of serum sodium correction

Overly rapid increases in serum sodium concentration can lead to serious sequelae.³ For that reason, it is important to monitor patients frequently and to avoid serum sodium increases of >12 mEq/L/24 h.^2,3

NEXT: Video Presentation—Management of Hyponatremia

References: 1. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(suppl 11A):S1-S21. 2. Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med. 2006;73(suppl 3):S4-S12. 3. Vaprisol Prescribing Information. Astellas Pharma US, Inc.

Stay Informed

Click here

Vaprisol Works Differently—Find Out How

Learn more about how first-in-class Vaprisol targets AVP to lower serum [Na⁺].

Click Here

Vaprisol Provides Proven Efficacy

Learn more about how Vaprisol raises serum [Na⁺] in a prompt but controlled fashion.

Click here

Indication

Vaprisol is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients
Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events

Important Safety Information

Vaprisol is contraindicated in patients with hypovolemic hyponatremia. In addition, coadministration of Vaprisol with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated
Serum sodium, volume, and neurological status must be monitored frequently because Vaprisol potentially can cause overly rapid correction of sodium leading to serious sequelae
The use of Vaprisol in patients with hepatic impairment (including ascites, cirrhosis, or portal hypertension) or renal impairment has not been systematically evaluated. Use caution when administering Vaprisol to these patients
The most common adverse reactions reported were infusion site reactions (incidence of 73% and 63% for 20 mg/day and 40 mg/day, respectively) which were also the most common type of adverse reaction leading to discontinuation of Vaprisol. Discontinuations from treatment due to infusion site reactions were more common among Vaprisol-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20 mg/day and 40 mg/day, respectively